Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783172 · ClinicalTrials.gov registry record · Phase 1
Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT00783172 is a Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 4 participants.
The verdict
NCT00783172, a Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer. The study includes two aims, the first is to evaluate the safety and toxicity of the combination of OGF and gemcitabine chemotherapy. The second aim of the trial is to study the efficacy of OGF and gemcitabine when used in combination.
Interventions
- DRUG Gemcitabine
- BIOLOGICAL Opioid Growth Factor (OGF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783172
The ClinicalTrials.gov registry entry for NCT00783172 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00783172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00783172 about?
NCT00783172 is a clinical study titled "Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer". It is hypothesized that OGF biotherapy may be safely administered in combination with gemcitabine to individuals with unresectable pancreatic cancer. The study includes two aims, the first is to evaluate the safety and toxicity of the combination of OGF and gemcitabine chemotherapy. The second aim o...
What is the current status of trial NCT00783172?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2009-01. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00783172?
The interventions under investigation include: Gemcitabine (DRUG), Opioid Growth Factor (OGF) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00783172?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.